Individualized Pazopanib Dosing-Letter

Audrey Bellesoeur; Pascaline Boudou-Rouquette; Audrey Thomas-Schoemann; Charlotte Joly; Camille Tlemsani; Michel Vidal; François Goldwasser; Benoit Blanchet

doi:10.1158/1078-0432.CCR-17-1873

Individualized Pazopanib Dosing-Letter

Clin Cancer Res. 2017 Oct 15;23(20):6377. doi: 10.1158/1078-0432.CCR-17-1873.

Authors

Audrey Bellesoeur^{1

2

3}, Pascaline Boudou-Rouquette^{1

2

3}, Audrey Thomas-Schoemann^{4

3}, Charlotte Joly⁵, Camille Tlemsani^{1

2

3}, Michel Vidal^{6

3}, François Goldwasser^{1

2

3}, Benoit Blanchet^{6

3}

Affiliations

¹ Department of Medical Oncology, Hôpital Cochin, AP-HP, Paris, France.
² Université Paris Descartes, Paris, France.
³ CARPEM, Paris, France.
⁴ Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France. audrey.bellesoeur@aphp.fr.
⁵ Department of Medical Oncology, Hôpital Henri Mondor, AP-HP, Paris, France.
⁶ Department of Pharmacokinetics and Pharmacochemisty, Hôpital Cochin, AP-HP, Paris, France.

PMID: 29030334
DOI: 10.1158/1078-0432.CCR-17-1873

No abstract available

Publication types

Letter

MeSH terms

Angiogenesis Inhibitors* / administration & dosage
Humans
Indazoles
Pyrimidines* / administration & dosage
Sulfonamides* / administration & dosage

Substances

Angiogenesis Inhibitors
Indazoles
Pyrimidines
Sulfonamides
pazopanib